BeyondSpring Inc
Research BeyondSpring Inc (BYSI) on Bullrun: market cap USD 29.61M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBYSI
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 29.61M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 2.16M
- Free cash flow-USD 3.28M
Valuation Snapshot
latest market cap is USD 29.61M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 1.01M | -USD 19.82M | n/a | 0.01 | USD 7.79M | USD 320.00K | -USD 32.16M |
| FY2024 | USD 0 | -USD 11.12M | -USD 16.67M | n/a | -0.51 | USD 2.92M | USD 589.00K | -USD 32.90M |
| FY2023 | USD 0 | -USD 21.03M | -USD 16.57M | n/a | n/a | USD 5.40M | USD 847.00K | -USD 26.81M |
| FY2022 | USD 1.35M | -USD 33.28M | -USD 27.50M | n/a | n/a | USD 34.40M | USD 0 | -USD 5.98M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 29.61M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 67.03M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 65.72M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 35.11M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 73.24M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 176.34M | n/a | n/a | n/a |
About BeyondSpring Inc
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform. The company's lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC);
Related stock research
Other Healthcare stocks
Frequently asked questions
What is BeyondSpring Inc's market cap?
BeyondSpring Inc's market capitalization is USD 29.61M.
What does BeyondSpring Inc do?
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform. The company's lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia (CIN).